Research on the Path of Chinese Pharmaceutical Enterprises Going Public based on the Comprehensive Registration System

Lixin Chen

doi:10.54097/hbem.v15i.9350

Authors

Lixin Chen

DOI:

https://doi.org/10.54097/hbem.v15i.9350

Keywords:

Going Public; Comprehensive Registration System; Chinese Pharmaceutical Enterprises; Path.

Abstract

Due to the characteristics of high investment, high risk, and high return in pharmaceutical enterprises, pharmaceutical enterprises have different capital requirements from other industries. At the same time, China's pharmaceutical industry has a late start and rapid development therefore, there are few innovative projects but mainly imitation, leading to characteristics of repetitive production and insufficient stamina, as well as imperfect enterprise systems, and a relative lack of financing channels. With the recent domestic stock issuance registration system, the difficulty in issuing finance for pharmaceutical enterprises is expected to be resolved. This article reviews the financing history of pharmaceutical enterprises in China, compares the characteristics and listing conditions of A-share, Hong Kong share, and US share registration systems, and proposes relevant measures to promote the rapid development of pharmaceutical enterprises in China by using the capital market.

Downloads

Download data is not yet available.

References

J Fu. Analysis and Suggestions on the Development Status of China's Biopharmaceutical Industry [J]. Special Economic Zone, 2014 (04): 70-71.

J Ding, N Ji, X Li, et al. Analysis of China's biomedical innovation investment and its policy causes: an empirical evaluation based on the current situation of innovation investment in China, the United States and Europe [J]. Scientific Management Research, 2012, 30 (04): 10-14.

Sharon Belenzon. Cumulative Innovation and Market Value: Evidence from Patent Citations*. 2012, 122(559):265-285.

Z Rong. Current Situation and Development Prospect of Modern Biopharmaceutical Industry [J]. Chemical Technology Market, 2002 (11): 7-12+30.

S Wen. Development Trend of the Global Biopharmaceutical Industry [J]. China Journal of Biotechnology, 2006 (01): 92-96.

F Hao. Research on the American Biomedical Industry Based on Innovation Networks [J]. Science of Science Research, 2005 (S1): 288-291.

Y Xia, M Zhao. The development path of China's biopharmaceutical industry in the context of supply side reform [J]. Hubei Agricultural Science, 2016, 55 (21): 5686-5689+5693.

X Tian, Y Hu. Promoting the Construction of "High Precision and Advanced" Industrial Structure through Supply-side Structural Reform -- Taking Beijing as an Example [J]. Economic and Management Research, 2016, 37 (08): 32-42.

C Li. Arrangements and Changes of China's Stock Issuance Approval System [J]. Financial Theory and Practice, 2000 (01): 50-52.

Z Zhang, J Teng. Can the registration system inquiry reform improve IPO pricing efficiency? -Research perspective based on the pilot registration system reform of the Science and Technology Innovation Board [J]. Shanghai Finance, 2020 (08): 24-30.

Saez-Ibañez AR, Upadhaya S, Partridge T, et al. Landscape of cancer cell therapies: trends and real-world data [J]. Nat Rev Drug Discov, 2022(9):631-632.

Guanqiao Li, Yale Jiang, Yunhe Qin, et al. comparing development strategies for PD1/PDL1-based immunotherapies [J]. Nat Rev Drug Discov, 2022(7):484.